RNA-Based Reprogramming of Airway Basal Cells for Pure iPSC Generation

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods for generating pure airway basal cells for treating chronic airway diseases are inefficient, as they fail to produce a homogeneous population of cells capable of differentiating into normal mucociliary epithelium without genetic manipulation or contamination by other cell lineages.

Innovation Solution

A virus-, DNA-, and integration-free RNA-based reprogramming method is used to generate induced pluripotent stem cells (iPSCs) from nasal and bronchial airway basal epithelial cells, which are then directed to differentiate into induced basal cells (iBCs) using a series of culture techniques that include SMAD inhibition and ROCK inhibition, resulting in a population that is at least 80% positive for basal cell markers KRT5, TP63, and NKX2.1 without genetic manipulation.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Manufacturing precision

If stepwise differentiation protocols are used to generate airway basal cells from iPSCs, then lung progenitors including airway basal cells can be specified, but a pure airway basal cell population cannot be achieved

Engineering Contradiction:

Improvepurity of airway basal cell populationVSAvoidefficiency of generating pure basal cells

Core Design Contradiction:

Manufacturing precisionVSProductivity

Solution Approach 1:

The differentiation process is divided into distinct stages: endoderm formation, foregut specification, lung progenitor generation, and finally airway basal cell differentiation. Each stage uses specific culture conditions and growth factors to guide cells through sequential transitions, enabling isolation of pure basal cell populations at the final stage rather than attempting to generate them directly

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The protocol performs preliminary differentiation steps to generate intermediate cell types (endoderm, foregut, lung progenitors) before finally producing airway basal cells. This preliminary action through staged differentiation ensures that when basal cells are generated, they are pure and functional, resolving the contradiction between purity and efficiency

Inventive Principle:

Principle #10Preliminary action

2Reliability

If virus- and DNA-based reprogramming methods are used to generate iPSCs, then pluripotent stem cells can be produced, but genetic manipulation and integration occur

Engineering Contradiction:

Improvepluripotency of generated cellsVSAvoidgenetic manipulation and contamination

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent replaces viral and DNA-based reprogramming methods with small molecule-induced reprogramming. Small molecules act through biochemical pathways to induce pluripotency without integrating genetic material into the genome, eliminating the harmful effects of viral integration and transgene expression while maintaining reliable pluripotency induction

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

Solution Approach 2:

The use of small molecules as reprogramming factors provides a transient, non-integrating approach compared to permanent viral or plasmid-based methods. These small molecules act temporarily to induce pluripotency and can be washed away, leaving no permanent genetic footprint, thus eliminating contamination risks

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

3Manufacturing precision

If conventional differentiation methods are used, then lung progenitors can be generated, but normal mucociliary epithelium cannot be produced

Engineering Contradiction:

Improvenormal differentiation into mucociliary epitheliumVSAvoidcomplexity of culture techniques

Core Design Contradiction:

Manufacturing precisionVSDevice complexity

Solution Approach 1:

The protocol applies specific local conditions at each differentiation stage: particular growth factors, extracellular matrix compositions, and culture medium formulations are used to guide cells through endoderm, foregut, and lung progenitor stages before final airway basal cell differentiation. These localized quality controls ensure proper maturation into functional mucociliary epithelium

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The differentiation protocol dynamically adjusts culture conditions through sequential stages, changing growth factors, medium composition, and cellular environment as cells progress from undifferentiated iPSCs through various progenitor stages to final airway basal cells. This dynamic adaptation of culture conditions enables proper epithelium formation while managing complexity through systematic progression

Inventive Principle:

Principle #15Dynamics

Data Source

PatentUS20230138022A1Methods of making pluripotent stem cells and uses thereof

Publication Date: 2023.05.04 NAT JEWISH HEALTH

AI summary

Disclosed herein are methods to reliably and robustly generate a pure population of airway basal cells that are capable of producing a normal mucociliary epithelium. Such basal cells may be used to treat chronic respiratory diseases, such as cystic fibrosis, chronic obstructive pulmonary disease, and asthma.